Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vistin Pharma ASA is a Norway-based holding company operating in the pharmaceuticals sector through its subsidiary Vistin Pharma AS. It specializes in the production and global supply of metformin HCl active pharmaceutical ingredients (APIs) and direct compressive granulates, essential for medications treating type 2 diabetes. As a dedicated European producer, Vistin Pharma ASA emphasizes high-quality manufacturing, environmental sustainability, social responsibility, and ethical practices to meet the demands of international pharmaceutical companies. Founded in 1969 and headquartered in Oslo, the company serves diverse markets including Europe, Africa, Asia, and the Americas, with sales primarily concentrated in Europe. Employing around 73 people, it maintains a focused operation in generic pharmaceuticals, positioning itself as a reliable supplier in the growing global diabetes treatment market. Key leadership includes CEO Magnus Tolleshaug and Chairman Øyvin Anders Brøymer, supported by a board of experienced directors. Vistin Pharma ASA plays a vital role in ensuring stable supply chains for critical diabetes therapies.
NOK 1.80
+NOK 0.02 (+1.13%)
EOD Jul 1, 2026
Margins and capital returns are both well above average: 20.42% operating margin, ROIC at 22.50%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 5.3%, steady but not accelerating.
Even for strong businesses, today's 1x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
1.1x earnings, 1.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 449M
▲ +5.3% YoY
Net Income (TTM)
NOK 75M
▲ +19.1% YoY
Op. Margin
19.70%
▲ +0.6pp YoY
ROIC
22.50%
▲ +1.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
NOK 51M
▼ -9.2% YoY
Op. Cash Flow (TTM)
NOK 78M
▼ -12.1% YoY
Net Debt
-NOK 16M
Net Cash Position
Cash & Equiv.
NOK 16M
3Y CAGR: +16.3%
Continue Research
At a P/E of 1.1 and a price-to-free-cash-flow of 1.6, Vistin Pharma ASA (VISTN.XOSL) trades below a two-stage DCF intrinsic value of about NOK 20.38 per share, so at NOK 1.80 the stock looks undervalued (1,035.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vistin Pharma ASA scores 81/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 69.5%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about NOK 20.38 per share for VISTN.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 15.29. At today's NOK 1.80, that puts the stock about 1,035.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Vistin Pharma ASA scores 81 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 19.7% operating margin and a 22.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Vistin Pharma ASA pays a regular dividend of about NOK 1.25 per share per year (typically in quarterly installments), a yield of roughly 69.5% at the current price. That is a payout ratio of about 74.4% of earnings, so the dividend is covered, with less cushion. Vistin Pharma ASA has grown the dividend at roughly 58.1% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For VISTN.XOSL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. VISTN.XOSL currently trades below its estimated intrinsic value and scores 81/100 on quality (high-quality). It also yields about 69.5%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.